We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, Managing Director of Novo Nordisk India, in an interview with Moneycontrol.

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery slimming of Bollywood filmmaker Karan Johar and TV talk show host Kapil Sharma ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...

Global capability centres, which employ 2.1 million people, are reshaping global business models in India, powered by innovation, AI, and talent from emerging cities. Can they transform India's job ...

Chhattisgarh High Court voids Section 263 revision order against Shilphy Steels, ruling it invalid due to lack of reasonable ...

MUMBAI: Danish drug giant Novo Nordisk is aiming to hit $1 billion (Rs 8,600 crore) sales in India with its blockbuster weight-loss drug Wegovy (semaglutide) in five to seven years. To reach that ...

The Indian Institute of Management Ahmedabad on Wednesday said it has signed an agreement with Novo Nordisk India to ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most populous ...

While Lilly and Novo are still the only two companies with approved weight-loss drugs on sale in the U.S., others are coming for a share of the growing sector.